Related Experiment Videos
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors
Lovisa Afzelius1, Ismael Zamora, Collen M Masimirembwa
1DMPK and Bioanalytical Chemistry, AstraZeneca R&D, S-431 83 Mölndal, Sweden. Afzelius@astrazeneca.com
Journal of Medicinal Chemistry
|February 6, 2004
Summary
A new 3D-QSAR model predicts drug interactions with CYP2C9 without needing molecular alignment or protein structures. This flexible approach accurately identifies competitive inhibitors, aiding drug discovery.
Area of Science:
- Computational chemistry
- Medicinal chemistry
- Drug discovery
Background:
- Drug-metabolizing enzymes like Cytochrome P450 (CYP) are crucial targets for drug development.
- Developing accurate structure-activity relationship (3D-QSAR) models is essential for predicting drug efficacy and toxicity.
- Existing 3D-QSAR methods often require predefined molecular alignments, limiting their applicability to diverse chemical structures.
Purpose of the Study:
- To develop a novel conformer- and alignment-independent 3D-QSAR model for predicting inhibitors of the drug-metabolizing enzyme CYP2C9.
- To validate the model's predictive power using a diverse set of competitive inhibitors.
- To demonstrate a method for generating predictive 3D-QSAR models without requiring ligand alignment or target protein structural information.
Main Methods:
- Utilized flexible molecular interaction fields calculated with GRID software.
- Employed alignment-independent descriptors generated by ALMOND software.
- Trained the model on a dataset of 22 diverse and flexible competitive CYP2C9 inhibitors.
- Validated the model's predictive capacity on an external test set of 12 competitive inhibitors.
Main Results:
- Achieved a high correlation coefficient (r^2) of 0.81 and cross-validated coefficient (q^2) of 0.62 for the training set.
- Externally validated the model, with 11 out of 12 inhibitors correctly predicted within 0.5 log unit.
- Identified key interaction points that correlated well with known amino acid residues in the CYP2C9 active site, supporting the model's mechanistic relevance.
Conclusions:
- The developed alignment-independent 3D-QSAR approach provides a robust and predictive model for CYP2C9 inhibitors.
- This method overcomes limitations of traditional 3D-QSAR by not requiring ligand alignment or protein structural data.
- The approach facilitates the development of predictive QSAR models for chemically diverse ligands, accelerating drug discovery and development efforts.